Prof. Dr. Mattia Intra
Viernes 12 de abril. 19 hs
Salón de la Academia Nacional de Ciencias
Av. Vélez Sarsfield 229
Antecedentes Curriculares del Prof. Dr. Mattia Intra
- Director de Cirugía del Instituto Europeo de Oncología de Milán. Italia.
- Prof. de las Universidades de Barcelona, Madrid (España) y de la Universidad de La Salle en México.
- Consultor de Mastología del Ministerio del Interior de Italia.
- Relator en mas de 160 Congresos Internacionales en Europa, Norte y Sudamérica, Asia y África.
Resumen de la Conferencia: PRESENT AND FUTURE OF THE SURGICAL TREATMENT OF BREAST CANCER – Dr. Mattia Intra
Surgery is usually the first treatment for breast cancer and is used to reduce the amount of cancer in the breast to the lowest possible level. Studies show that 80 percent of patients with small breast cancers that do not involve the lymph nodes will survive 20 years if treated with surgery alone. But surgery is not our only defense.
The last 30 years have given us a multitude of new medications — like hormone therapies and targeted drugs — that not only reduce the likelihood that cancer will return or spread to other parts of the body but also improve surgical outcomes by reducing local recurrence in the breast. In fact, the advent of effective systemic therapy has cut the likelihood of a local recurrence in half.
How is surgery for breast cancer evolving? The combination of surgery plus systemic therapy has been very successful in reducing tumor burden, and it’s unlikely that efforts to surgically reduce tumor burden even more will improve outcomes.
We are moving toward a more multimodality approach to treating breast cancer where local therapy, meaning surgery and radiation, and systemic therapy are considered together, rather than as three separate phases of treatment. We are also learning more about the biology of breast cancer, and future studies will need to address not only whether improvements in drug therapy will allow us to safely decrease the extent of surgery and radiation, but also how an individual patient’s biology should guide treatment decisions.